Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 7 of the 18 sources its claims cite were checked for support.
Abstract
Three randomized controlled trials, encompassing 878 patients, satisfied our inclusion criteria. Retatrutide significantly reduced body weight and improved metabolic outcomes. No significant difference in adverse events was observed between the groups (relative risk: 1.11, P = 0.24). Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis of three RCTs (878 patients) found retatrutide significantly reduced body weight and metabolic parameters versus placebo in obesity, with gastrointestinal adverse events more common at higher doses. The authors conclude retatrutide is promising but larger, longer trials are needed.
Key findings
- Pooled body weight reduction was MD −14.33% (95% CI −18.27 to −10.39, P < 0.00001) after 36 weeks; dose subgroups were 4 mg −9.86%, 8 mg −16.31%, and 12 mg −16.90%.
- Significant reductions were also reported for BMI (MD −5.38), waist circumference (MD −10.51 cm), fasting plasma glucose (MD −23.51 mg/dL), HbA1c (MD −0.91%), systolic blood pressure (MD −9.88 mm Hg), and diastolic blood pressure (MD −3.88 mm Hg), all with P < 0.00001.
- Odds ratios for achieving ≥5%, ≥10%, and ≥15% weight loss were 43.34, 89.84, and 46.93, respectively (all P < 0.00001).
- Overall adverse events were not significantly different at 4 mg (RR 1.11, P = 0.24), but were increased at 8 mg (RR 1.23, P = 0.007) and 12 mg (RR 1.34, P < 0.0001); nausea, vomiting, decreased appetite, diarrhea, and constipation were higher with retatrutide.
Methods
- Systematic review and meta-analysis following PRISMA and Cochrane Handbook standards; protocol registered in the Open Science Framework (10.17605/OSF.IO/EX2UD). PubMed, Scopus, Web of Science, and Cochrane were searched from inception until May 1, 2024.
- Included randomized controlled trials comparing retatrutide with placebo in obese or overweight patients with or without type 2 diabetes; excluded healthy populations, non-English texts, single-arm studies, animal studies, and abstracts. Three RCTs with 878 patients (748 retatrutide, 130 placebo) were included.
- RevMan 5.4 was used; continuous outcomes were pooled as mean differences and categorical outcomes as relative risks or odds ratios with 95% CIs. A random-effects model was used when I² > 60% or χ² P < 0.1; subgroup analysis was by dose (4 mg, 8 mg, 12 mg).
Limitations
- The paper states high heterogeneity in some analyses, a small number of included RCTs, small sample sizes, and a lack of long-term data on sustainability of weight loss and safety.
- The paper states that heterogeneity in most efficacy outcomes could not be resolved by leave-one-out or sensitivity analysis because only two studies were included in the efficacy analysis.
- Evident from the text: included trials were phase 1b/2 with short treatment durations (12–48 weeks), mostly conducted in the USA, and no head-to-head trials with other antiobesity medications were included.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
4 Valid · 0 Not valid · 3 Not checked · 37 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean differences for the 4, 8, and 12 mg groups were −9.86 (95% CI: −16.97 to −2.76, P = 0.006), −16.31 (95% CI: −21.49 to −11.13, P < 0.00001), and −16.90 (95% CI: −22.37 to −11.44, P < 0.00001).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No significant difference in adverse events was observed between the groups (relative risk: 1.11, P = 0.24).”
plainn = 878- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean differences for the 4, 8, and 12 mg groups were −9.86 (95% CI: −16.97 to −2.76, P = 0.006), −16.31 (95% CI: −21.49 to −11.13, P < 0.00001), and −16.90 (95% CI: −22.37 to −11.44, P < 0.00001).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The overall pooled analysis showed a statistically significant percent reduction in body weight of the retatrutide group when compared to the placebo group after 36 weeks of treatment, with an overall MD of −14.33 (95% CI: −18.27 to −10.39, P < 0.00001)”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The MD for the 4, 8, and 12 mg groups were as follows: −4.24 (95% CI: −4.88 to −3.60, P < 0.00001), −5.85 (95% CI: −6.46 to −5.24, P < 0.00001), and −6.00 (95% CI: −6.65 to −5.35, P < 0.00001), respectively.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
24 more claims
Create a free account to see all 44 claims and every source verdict.
- It may state two separate claims as one. 12
- Probably not a substantial claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although current studies demonstrate expressive reductions in hepatic fat, the evidence related to the regression of fibrosis, prevention of cirrhosis, and reduction of long-term hepatic complications remains limited.”
From RETATRUTIDE USE IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND OBESITY: AN INTEGRATIVE REVIEW (2026) · cites this paper as ABOUELMAGD et al., 2025
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, in silico modeling, in vitro receptor binding studies, and in vivo trials in both rodents and humans have demonstrated that receptor cross-talk and synergistic signaling can be exploited rather than avoided.”
From The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities (2026) · cites this paper as [43]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent reviews corroborate these findings and highlight that retatrutide presents an acceptable safety profile and the potential to become established as one of the main pharmacological strategies for the treatment of obesity and its metabolic complications”
From RETATRUTIDE USE IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND OBESITY: AN INTEGRATIVE REVIEW (2026) · cites this paper as ABOUELMAGD et al., 2025
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Results
“No significant difference in adverse events was observed between the groups (relative risk: 1.11, P = 0.24).”
§ RESULTS
“Nonetheless, the 8 mg dose showed a slight increase in adverse events with an RR of 1.23 (95% CI: 1.06 to 1.44, P = 0.007), and the 12 mg dose had a more pronounced increase in adverse events, with an RR of 1.34 (95% CI: 1.16 to 1.55, P < 0.0001).”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ RESULTS
“The 12 mg dose subgroup showed the greatest reduction with an MD of −1.54 (95% CI: −2.47 to −1.55, P = 0.14)”
§ RESULTS
“Retatrutide 12 Placebo 98 MD − 1.19 (95% CI: −2.77, 0.39) 0.14”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Retatrutide 4 mg combined 47 17(57.5%)”
Reported 17 · recomputed 27
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ RESULTS
“For the 4 mg dose subgroup, the MD was −17.80 (95% CI: −35.21 to −0.38, P = 0.05), with no significant heterogeneity (P = 0.07, I2 = 70%).”
§ METHODS
“In cases where significant heterogeneity was identified—I2 > 60% or χ2 P < 0.1—we employed a random effects model to compute pooled effect size; otherwise, a fixed-effect model was used.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Retatrutide 12 mg escalation 66 32 (52%)”
Reported 52 · recomputed 48.484848
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Rayyan-a web and mobile app for systematic reviews.
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0384-4 · Cited by 26,092
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · cited 2×
“Originally, given that weight loss is being increasingly acknowledged as a vital part of the treatment for T2DM, 29 one of the included trials in the efficacy meta-analysis tested retatrutide in patients with T2DM.”
De-duplication of database search results for systematic reviews in EndNote
Bramer, W. M., Giustini, D., de Jonge, G. B., Holland, L., & Bekhuis, T. (2016) · Journal of the Medical Library Association : JMLA · doi:10.3163/1536-5050.104.3.014 · Cited by 2,103 · cited 1×
“20 Following this, titles and abstracts were screened using Rayyan.”
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174 · cited 4×
“25 This combination might increase impacts on substrate utilization, energy intake, and energy expenditure.”
InfluentialIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Research works printed but not linked: 2
- Lobstein T, Jackson-Leach R, Powis J, Brinsden H, Gray M. World Obesity Atlas 2023. World Obes Fed. 2023;(March):5–25. www.johnclarksondesign.co.uk
- 10.1186/S13643-016-0384-4/FIGURES/6 · doi:10.1186/s13643-016-0384-4/figures/6
Cited by
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 53
“Retatrutide represents the current efficacy frontier, demonstrating up to 24.2% weight reduction in the 12 mg group at 48 weeks, approaching bariatric surgery levels without invasive intervention [72,79,80].”
InfluentialGanamurali, N., & Sabarathinam, S. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70001 · Cited by 8
Bujdei-Tebeică, I., Mihai, D. A., Stoian, A. P., Ștefan, S., Stoicescu, C. I., & Serafinceanu, C. (2025) · Medicina · doi:10.3390/medicina61081399 · Cited by 11
Tantoush, M., Almaghrabi, Y., Abusbaeh, A., Ahmed, N., Tantush, A., Hamida, B. B., Sagher, M., Sager, M., Abouslima, A., Elbahnasawy, S. E., et al. (2026) · Cureus · doi:10.7759/cureus.102018 · Cited by 7
“The consistency of weight reduction and glycemic control across different GLP-1 receptor agonist formulations reinforces the class effect of these therapeutic agents and supports orforglipron’s potential role in comprehensive cardiometabolic risk management [37,38].”
New therapeutic agents for type 2 diabetes: anaesthetic considerations. A narrative review
Doroba, O., Czupryniak, L., Sanfilippo, F., Andruszkiewicz, P., & Zawadka, M. (2025) · Anaesthesiology Intensive Therapy · doi:10.5114/ait/208895 · Cited by 6
Metadata
- Authors
- Abdrabou Abouelmagd, A., Abdelrehim, A. M., Bashir, M. N., Abdelsalam, F., Marey, A., Tanas, Y., Abuklish, D. M., & Belal, M. M.
- Affiliations
- Faculty of Medicine, South Valley University
- Misr University for Science and Technology (EG)
- Alexandria University (EG)
- Al-Azhar University (EG)
- Houston Methodist (US)
- Tripoli Central Hospital (LY)
- Corresponding author
- Belal, Mohamed Mohamed
- ORCID
- Venue
- Baylor University Medical Center Proceedings
- Publisher
- Informa UK Limited
- Published
- 2025-02-05
- Volume
- 38
- Issue
- 3
- Pages
- 291-303
- ISSN
- 0899-8280 (ISSN-L)
- 1525-3252
- PMC
- PMC12026077
- OpenAlex
- W4407175317
- Cited by
- 25
- References
- 32
- Citations by year
- 2026: 20 · 2025: 5
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Baylor University Medical Center Proceedings (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- retatrutide, obesity, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, weight loss, glycemic control, blood pressure, diabetes mellitus, drug safety, dose comparison
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1080/08998280.2025.2456441
- The paper
- Abdrabou Abouelmagd, A., Abdelrehim, A. M., Bashir, M. N., Abdelsalam, F., Marey, A., Tanas, Y., Abuklish, D. M., & Belal, M. M. (2025). Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Baylor University Medical Center Proceedings. https://doi.org/10.1080/08998280.2025.2456441
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


